sglt2 inhibitors + glp-1 receptor agonists + nonsteroidal mineralocorticoid receptor antagonists

This is a **combination therapy** that includes three pharmacological classes: **SGLT2 inhibitors**, **GLP-1 receptor agonists**, and **nonsteroidal mineralocorticoid receptor antagonists**. - **SGLT2 inhibitors** lower blood glucose by blocking the sodium-glucose co-transporter 2 in the kidney, promoting renal glucose excretion and reducing hyperglycemia; they also exert cardiovascular benefits likely through hemodynamic effects and are known to slow renal disease progression in type 2 diabetes mellitus[1][2][3]. - **GLP-1 receptor agonists** activate the glucagon-like peptide-1 receptor on pancreatic beta cells, increasing insulin secretion, decreasing glucagon secretion, reducing appetite, and slowing gastric emptying; these agents additionally exhibit anti-atherogenic and anti-inflammatory properties, and they reduce cardiovascular events and progression of renal disease[1][2][3]. - **Nonsteroidal mineralocorticoid receptor antagonists** (such as finerenone or esaxerenone) selectively block the mineralocorticoid receptor involved in kidney and cardiovascular fibrosis, inflammation, and sodium retention, providing further renoprotective and cardioprotective effects, especially in patients with diabetes and/or chronic kidney disease. All three classes have complementary mechanisms and additive benefits on glycemic control, weight loss, blood pressure reduction, and protection against cardiovascular and renal complications in type 2 diabetes and related disorders[1][2][3].